Research programme: platelet thrombin receptor antagonists - Merck & CoAlternative Names: PAR-1 antagonists research programme - Merck & Co; Platelet thrombin receptor antagonists research programme - Merck & Co; Research programme: PAR-1 antagonists - Merck & Co
Latest Information Update: 26 May 2010
At a glance
- Originator Merck & Co
- Class Small molecules
- Mechanism of Action PAR 1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 26 May 2010 Discontinued - Preclinical for Thrombosis in USA (unspecified route)
- 11 Sep 2000 Preclinical development for Thrombosis in USA (Unknown route)